𝔖 Bobbio Scriptorium

✦ LIBER ✦

PCN30 THE COSTS OF TREATING PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL CANCER (NSCLC) WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE COMPARED WITH PEMETREXED PLUS CISPLATIN IN INDUCTION AND MAINTENANCE THERAPY IN GERMANY AND ITALY

✍ Scribed by M Nuijten

Book ID: 118610865
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 88 KB
Volume: 12
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)73267-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN41 COST-SAVINGS ASSOCIATED WITH BEVAC

PCN41 COST-SAVINGS ASSOCIATED WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY

✍ D Heigener; HG Bischoff; C Wiesner; R Aultman 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

PCN87 A COST-EFFECTIVENESS ANALYSIS OF B

PCN87 A COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH PEMETREXED PLUS CISPLATIN (PC) FOR THE TREATMENT OF ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY

✍ HG Bischoff; D Heigener; C Wiesner; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PCN82 COST COMPARISON OF BEVACIZUMAB PLU

PCN82 COST COMPARISON OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE VERSUS PEMETREXED AND CISPLATIN THERAPY IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL CANCER IN GERMANY – AN UPDATED ANALYSIS

✍ HG Bischoff; A Hermes; DF Heigener; S Cesaro-Tadic; S Walzer; M Nuijten 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

PCN29 THE COST SAVINGS ASSOCIATED WITH B

PCN29 THE COST SAVINGS ASSOCIATED WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BEVACIZUMAB-BASED THERAPY) TREATMENT COMPARED WITH CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CETUXIMAB-BASED THERAPY) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL CANCER (NSCLC) ACROSS FOUR EUROPEAN COUNTRIES

✍ M Nuijten; C Chouaid; A Vergnenegre 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

9164 An indirect comparison of the effic

9164 An indirect comparison of the efficacy of bevacizumab plus cisplatin and gemcitabine (BCG) or bevacizumab plus carboplatin and paclitaxel (BCP) versus pemetrexed plus cisplatin (PC) and cetuximab plus vinorelbine and cisplatin (CVC) in patients (pts) with advanced or recurrent non-small cell cancer (NSCLC)

✍ Walzer, S.; de Castro Carpeno, J.; Vergnenegre, A.V.; Chouaid, C.; Heigener, D.F 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

A Cost-Effectiveness Analysis of Cisplat

A Cost-Effectiveness Analysis of Cisplatin Plus Pemetrexed Doublet Induction Treatment Followed by Pemetrexed Maintenance Compared with Bevacizumab Plus Cisplatin Plus Gemcitabine Triplet Induction Treatment Followed by Bevacizumab Maintenance for Non-Squamous NSCLC in Sweden

✍ Bryden, P.A.; Kumar, G.; Winfree, K.B.; Boye, M.E.; Taipale, K.; Thompson, R.; B 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB